MAP Insights

NICE Models for the evaluation and purchase of antimicrobials – what next?

In response to the challenges associated with discovering, developing and bringing new antimicrobial drugs to market, the National Institute for Health and Care Excellence (NICE) and NHS England and NHS Improvement (NHSE&I) developed a project to create a world-first pull incentive. Yesterday,  the project leapt forward as NICE published the draft guidance for cefiderocol and ceftazidime with avibactam.

Consensus on Antimicrobial resistance (AMR) call to action

Antimicrobial resistance (AMR) is a threat to our way of life. At the moment, it kills over 700,000 people each year globally (O’Neill 2016). However, it is the future threat that is truly existential: some estimates suggest that as many as 50 million people could die due to AMR each year by 2050 (O’Neill 2016). Innovation and development are the key to preventing this catastrophe.

Arrow Vector-Quotes